GlassScriptPhysician profile
Megan Camacho
NPI 1467163733
$2,997.92
in general payments reported to CMS, 2019-2025
23 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $335 · 2024: $1,351 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.76 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $314.11 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $283.24 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $283.22 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $201.16 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $198.89 | 2023-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $196.84 | 2023-2025 | |
| Amgen INC. | $169.06 | 2023-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $148.68 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.66 | 2024-2025 | Jardiance |
| Kyowa Kirin, INC. | $108.05 | 2024-2025 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $101.18 | 2024-2025 | |
| Cormedix INC. | $85.37 | 2024-2025 | Defencath, Defencath |
| Glaxosmithkline, LLC. | $74.89 | 2025 | Shingrix, Arexvy, Benlysta |
| Ascendis Pharma Endocrinology INC | $49.31 | 2025 | Yorvipath |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $48.80 | 2023 | Monoferric |
| Janssen Pharmaceuticals, INC | $36.62 | 2024 | Xarelto |
| Apellis Pharmaceuticals, INC. | $33.96 | 2025 | |
| Scpharmaceuticals INC. | $28.94 | 2025 | |
| Akebia Therapeutics INC | $27.24 | 2024 | Vafseo |
| Xeris Pharmaceuticals, INC. | $22.53 | 2024 | Keveyis |
| Fresenius USA Marketing, INC. | $19.00 | 2024 | Velphoro |
| Ani Pharmaceuticals, INC. | $17.41 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.